Type 2 Diabetes Mellitus
Conditions
Keywords
Adipokines, leptin, chemerin, omentin, metformin, type 2 diabetes mellitus
Brief summary
Oral hypoglycemic agents encompass the mainstay of treatment in the majority of patients with type 2 diabetes. Thiazolidinediones (such a pioglitazone) and Biguanides (such as metformin), are two major groups of hypoglycemic medications that while function via different pathways, are both effective in short- and long-term glycemic control . These medications diminish or at least delay long term micro- and macrovascular complications associated with prolonged insulin resistance although at different rates. The mechanisms by which this aim is achieved, nevertheless, remains largely unclear. With adipokines playing a key role in development of both insulin resistance and atherosclerosis, oral hypoglycemic agents might regulate these substances by direct and indirect routes.
Interventions
DRUGMetformin
Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
DRUGPioglitazone
Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
Sponsors
Tehran University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed type 2 diabetes patients based on American Diabetes Association criteria (2011) for diagnosis of diabetes
Exclusion criteria
* previous intake of oral hypoglycemic agents for treatment of diabetes or other hyperglycemia associated conditions * intake of glucocorticoids in the past one year * major illnesses of heart, lung, kidney, and liver.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum concentrations of omentin | 12 weeks | Serum concentrations of adipose tissue derived cytokine omentin |
| Serum concentrations of leptin | 12 weeks | Serum concentrations of adipose tissue derived cytokine leptin |
Countries
Iran
Outcome results
None listed